Who are ropivacaine plus clonidine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): clonidine, levobupivacaine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ropivacaine-plus-clonidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ropivacaine plus clonidine — Competitive Intelligence Brief

ropivacaine plus clonidine (ropivacaine plus clonidine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic with adjuvant alpha-2 agonist. Area: Anesthesia.

marketed Local anesthetic with adjuvant alpha-2 agonist Voltage-gated sodium channels (ropivacaine); alpha-2 adrenergic receptors (clonidine) Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

ropivacaine plus clonidine (ropivacaine plus clonidine) — University Hospital, Lille. Ropivacaine blocks sodium channels to provide local anesthesia, while clonidine enhances analgesia by activating alpha-2 adrenergic receptors.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ropivacaine plus clonidine TARGET	ropivacaine plus clonidine	University Hospital, Lille	marketed	Local anesthetic with adjuvant alpha-2 agonist	Voltage-gated sodium channels (ropivacaine); alpha-2 adrenergic receptors (clonidine)
clonidine, levobupivacaine	clonidine, levobupivacaine	University Hospital Dubrava	marketed	Local anesthetic with adjuvant alpha-2 agonist	Alpha-2 adrenergic receptor (clonidine); voltage-gated sodium channels (levobupivacaine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic with adjuvant alpha-2 agonist class)

University Hospital Dubrava · 1 drug in this class
University Hospital, Lille · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ropivacaine plus clonidine — Competitive Intelligence Brief. https://druglandscape.com/ci/ropivacaine-plus-clonidine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab